Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Semaglutide in Line for March Approval as Obesity Drug, Precedex Too
January 30, 2023
- Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
January 30, 2023
- Japan Should Stick to Current COVID Vaccination System: Panel Members
January 27, 2023
- Experts Doubt Necessity of Policy Intervention for LLP-Dependent Companies
January 27, 2023
- Expert Panel Member Alarmed by Stagnation of Biosimilar Business in Japan
January 27, 2023
- MHLW to Support Development of Drugs and Vaccines for Infectious Diseases from PIII Onwards: Counsellor
January 26, 2023
- Chuikyo Begins Xocova Price Debate under Mega Seller Rule, Weighs Quicker Re-Pricing
January 26, 2023
- Japan to Revise Revlimid Risk Management Rule in June; February Generic Approval Eyed
January 25, 2023
- MHLW Warns of Inadvertent Xocova Use in Pregnant Women after 2 Cases Reported
January 25, 2023
- MHLW Details Plan to Ensure Stable Supplies of β-Lactam Antibiotics
January 24, 2023
- PM Kishida Hails Lecanemab as World’s First Innovative AD Drug Originating from Japan
January 24, 2023
- MHLW Panel OKs 62 More Health Damage Claims for COVID-19 Vaccines
January 24, 2023
- Xocova Might Trigger Mega Seller Price Control Rule for First Time
January 24, 2023
- Setting “Presumed Efficacy” Criteria Would Be Difficult; Xocova Decision Reasonable: PMDA Chief
January 23, 2023
- First Abortion Pill Candidate in Japan Up for Panel Review on Jan. 27
January 23, 2023
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
January 23, 2023
- PMDA Reviewing Safety Risks for GLP-1 Agents
January 23, 2023
- Label Revision Ordered for Acetaminophen to Add Drug-Induced Hypersensitivity Syndrome as ADR
January 19, 2023
- Label Expansions for Nubeqa, Rinvoq, Imbruvica on PAFSC Agenda for Feb. 1
January 19, 2023
- Chuikyo’s Drug Pricing Debate Slated to Begin in May after Expert Panel Proposal
January 19, 2023
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…